HC Wainwright Rates Unicycive Therapeutics (UNCY) buy

Wall Street firms keep updating their outlooks on Unicycive Therapeutics as the clinical-stage biotech company develops treatments for kidney diseases, a 226.80% upside from the current price.

By TradeTexts Research Desk · Published Jun 30, 2026, 2:02 PM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Unicycive Therapeutics, Inc. ($UNCY) "buy" with a $15 price target on June 30, 2026.

Since the rating, $UNCY is up 15.8% after 1 week, up 13.0% after 1 month and down 28.4% to date (from the $4.69 close on Jun 30, 2026).

UNCY Unicycive Therapeutics, Inc.

$3.36 -42.07% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright maintained its buy rating on Unicycive Therapeutics, Inc. (NASDAQCM: UNCY) on June 30, 2026, setting a $15.00 price target.
HC Wainwright's $15 price target implies 226.80% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.59 share price.
The stock traded around $4.59 recently, well below its 50-day moving average of $5.22 and its 200-day moving average of $6.38.
A group of 10 analysts follows the biotechnology company, with consensus targets stretching from a low of $15.00 up to $50.00.

Get $UNCY trade alerts by text

We text you when insiders, Congress or big funds trade $UNCY. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Unicycive Therapeutics, Inc. alert may contain errors. Disclosures

HC Wainwright Updates Its Outlook on Unicycive Therapeutics

HC Wainwright recently revisited its stance on Unicycive Therapeutics, Inc. (NASDAQCM: UNCY), keeping a positive view on the biotechnology firm. On June 30, 2026, analyst Swayampakula Ramakanth maintained a buy rating on the shares while adjusting the price target to $15.00. This update is part of a string of recent evaluations from healthcare specialists tracking the clinical-stage developer as it works through its drug pipeline.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +63.68% hypothetical

All-time return +172.49% S&P 500 +29.04%

vs. S&P 500 +143.45% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Wall Street Analyst Coverage and Price Targets

A broad group of financial firms continues to monitor Unicycive Therapeutics closely. On June 30, 2026, B. Riley Securities also maintained a buy rating on the stock with a $22.00 price target. Later in the summer, Benchmark maintained a speculative buy rating on August 20, 2026, with a $15.00 target, following an earlier review at $13.00 on July 1, 2026. Guggenheim maintained a buy rating with a $25.00 target on August 13, 2026. Noble Capital Markets kept an outperform rating with a target of $50.00 on July 1, 2026. More recently, on September 29, 2026, HC Wainwright maintained its buy rating while adjusting its target to $13.00. Across the broader analyst community, 10 analysts share a mean price target of $29.60, with individual forecasts spanning between $15.00 and $50.00.

Stock Performance and Trading Levels

The company's shares recently changed hands at a spot price of $4.59 on Tuesday. That price sits inside a 52-week trading window that spans from a low of $3.71 up to a high of $8.74. Short-term and long-term moving averages provide further context for where the stock trades right now, with the 50-day moving average resting at $5.22 and the 200-day moving average sitting at $6.38. With a market capitalization of $132.87 million, the stock experiences regular coverage shifts as clinical milestones approach.

12-month forecast

$UNCY price target

Unicycive Therapeutics, Inc. daily closes and this analyst's $15 target. Not advice.

Inside Unicycive Therapeutics and Its Pipeline

Unicycive Therapeutics operates as a clinical-stage biotechnology company based in Mountain View, California, focused on discovering and commercializing novel treatments for kidney diseases. The firm develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent intended to treat hyperphosphatemia in chronic kidney disease patients undergoing dialysis. In addition, the company is advancing UNI-494, a nicotinamide ester derivative acting as a selective ATP-sensitive mitochondrial potassium channel activator, currently evaluated in early clinical trials for acute kidney injury and pre-clinical stages for chronic kidney disease. Led by CEO Dr. Shalabh K. Gupta, the organization employs a small team of 21 people dedicated to nephrology solutions.

What to Watch Ahead

Investors and analysts are keeping an eye on the company's financial health and upcoming catalysts. The business carries a forward P/E ratio of 2.87 alongside a negative earnings per share of $1.75. The next corporate earnings update is scheduled for November 12, 2026, when management is expected to share further details on clinical progress and operational spending.